Are Probiotics the New Calcium and Vitamin D for Bone Health?
Bone Density Conservation Agents
/ therapeutic use
Bone Resorption
/ microbiology
Calcium
/ metabolism
Cultured Milk Products
Diabetes Complications
/ microbiology
Diabetes Mellitus
Gastrointestinal Microbiome
Glucocorticoids
/ adverse effects
Humans
Osteoblasts
Osteoclasts
Osteogenesis
Osteoporosis
/ etiology
Osteoporosis, Postmenopausal
/ microbiology
Probiotics
/ therapeutic use
Vitamin D
/ therapeutic use
Bone mineral density (BMD)
Bone turnover
Dairy products
Gut microbiota
Intestinal absorption
Nutrition
Osteoporosis
Journal
Current osteoporosis reports
ISSN: 1544-2241
Titre abrégé: Curr Osteoporos Rep
Pays: United States
ID NLM: 101176492
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
15
4
2020
medline:
19
8
2021
entrez:
15
4
2020
Statut:
ppublish
Résumé
Calcium and vitamin D supplementation is recommended for patients at high risk of fracture and/or for those receiving pharmacological osteoporosis treatments. Probiotics are micro-organisms conferring a health benefit on the host when administered in adequate amounts, likely by influencing gut microbiota (GM) composition and/or function. GM has been shown to influence various determinants of bone health. In animal models, probiotics prevent bone loss associated with estrogen deficiency, diabetes, or glucocorticoid treatments, by modulating both bone resorption by osteoclasts and bone formation by osteoblast. In humans, they interfere with 25-hydroxyvitamin D levels, and calcium intake and absorption, and slightly decrease bone loss in elderly postmenopausal women, in a quite similar magnitude as observed with calcium ± vitamin D supplements. A dietary source of probiotics is fermented dairy products which can improve calcium balance, prevent secondary hyperparathyroidism, and attenuate age-related increase of bone resorption and bone loss. Additional studies are required to determine whether probiotics or any other interventions targeting GM and its metabolites may be adjuvant treatment to calcium and vitamin D or anti-osteoporotic drugs in the general management of patients with bone fragility.
Identifiants
pubmed: 32285249
doi: 10.1007/s11914-020-00591-6
pii: 10.1007/s11914-020-00591-6
doi:
Substances chimiques
Bone Density Conservation Agents
0
Glucocorticoids
0
Vitamin D
1406-16-2
Calcium
SY7Q814VUP
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM